Geron Corporation (GERN:NASDAQ) closed at $1.13 on October 22, 2026, down 2.59% on the day. The stock trades 43.8% below its 52-week high of $2.01 and 8.7% above its 52-week low of $1.04. Over the past year, it lost 6.5%. Geron Corporation is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 22, 2025, GERN closed higher on 98 days (39%). Its best day was August 5, 2026 (+21.64%) and its worst was February 25, 2026 (-11.79%). The stock moved 10% or more in a single session 6 times.
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Find more stocks like GERN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.